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CORRELATION OF WEIGHT TO CARDIOMETABOLIC RISK AS
IDENTIFIED BY ICD-9 DIAGNOSIS CODES AND
PRESCRIPTIONS IN PRIMARY CARE
Brixner DI, Said Q, Ghate S, McAdam-Marx C
University of Utah, Salt Lake City, UT, USA
OBJECTIVES: This study evaluated the association of patients
with a BMI > 27 kg/m2 vs. a BMI °Y´18 and °Ü27 kg/m2 with car-
diometabolic risk factors (CMRFs). METHODS: A retrospective
review of an Electronic Medical Record database containing
ambulatory health record data for a nationally representative
sample of over 5 million US citizens with a BMI °Y´18 kg/m2 and
°Y´18 years of age was conducted. Patients with a valid BMI were
included and stratiﬁed by no CMRFs or with one or more diag-
noses or prescription orders associated with high triglycerides
(TG), low high density lipoprotein (HDL), type 2 diabetes or
hypertension two years prior to the last observation date.
RESULTS: A total of 499,594 patients were identiﬁed in the
study where 56% (281,988) had a BMI > 27 with a CMRF dis-
tribution of none (49.79%) one (35.36%) two (13.01%), three
(1.70%) or four (0.14%). Of those with one risk factor 141,852
(31.29%) had hypertension, 10,866 (2.90%) had diabetes, 3667
(0.92%) had increased TGs and 1201 (0.26%) had low HDL.
Compared to patients with no risk factors patients with 1–4 risk
factors were signiﬁcantly more likely to be in the >27 kg/m2
group in all cases (p < 0.001). Odds rations were 2.64 for hyper-
tension, 2.21 for elevated triglycerides, 1.91 for diabetes and
1.45 for low HDL; 3.58 for any 2 risk factors, 4.24 for any 3
risk factors and 5.07 for all 4 risk factors, relative to having 
no CMRFs. CONCLUSION: Patients with CMRFs including
hypertension, elevated triglycerides, diabetes or low HDL were
anywhere from 5.07 to 1.45 times more likely to be have a BMI
> 27. Diagnoses and treatments for CMRFs may be used as sur-
rogate measures for the presence of obesity in claims data. Drugs
that decrease both weight and improve CMRFs in such patients
could be beneﬁcial.
OB4
THE RELATIONSHIP BETWEEN OBESITY AND HEALTH-
RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE
TO SEVERE PSORIASIS OR RHEUMATOID ARTHRITIS
Eisenberg DF, Hanlon A, Segal J
Temple University, Philadelphia, PA, USA
OBJECTIVES: To explore the relationship between obesity and
health-related quality of life (HRQoL) in patients with moder-
ate to severe psoriasis (PsO) or rheumatoid arthritis (RA).
METHODS: A retrospective analysis on secondary clinical 
trial assessed 1205 PsO and 1988 RA patients using several
approaches: (1) two univariate regression analyses [obesity pre-
dicting HRQoL; disease severity predicting HRQoL] and (2) a
stepwise multivariate multiple regression analysis (MVA) to
assess obesity as an independent predictor of HRQoL. Disease
severity was measured using the PASI for PsO and DAS for RA.
SF-36 was used for HRQoL assessment in both diseases.
RESULTS: Obesity and disease severity were found to be signif-
icant predictors of HRQoL. The stepwise MVA, using BMI, age,
sex, disease duration and disease severity as predictors, revealed
an overall signiﬁcant effect in the PsO sample [components: L =
0.84, F (10, 2396) = 21.10, p < 0.0001; SF-36 domains: L = 0.73,
F (40, 5198.6) = 9.54, p < 0.0001]. BMI added to the prediction
of HRQoL over PASI for several SF-36 components and
domains: PCS, MCS, PF, RE, SF, VT and MH. The results of the
RA sample were similar: the overall MVA was signiﬁcant [com-
ponents: L = 0.74, F (10, 3962) = 64.05, p < 0.0001; SF-36
domains: L = 0.61, F (40, 8611.9) = 25.81]. Again, BMI added
to the prediction of HRQoL over disease severity for MCS, PF
and VT. Effect sizes in both samples were weak. CONCLUSION:
Obesity was an independent predictor of HRQoL when using
other covariates. This data indicates that reducing BMI and
disease severity contribute signiﬁcantly to the HRQoL of mod-
erate to severe PsO and RA patients.
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HOSPITAL COMPLIANCE WITH ACCP GUIDELINES FOR
ANTICOAGULANT THERAPY AND JCAHO PERFORMANCE
MEASURES
Vats V1, Nutescu EA1,Theobald JC2,Wojtynek JE2, Schumock GT1
1University of Illinois at Chicago, Chicago, IL, USA, 2Consorta Inc,
Schaumburg, IL, USA
OBJECTIVES: To (1) evaluate compliance with American
College of Chest Physicians (ACCP) guidelines for anticoagulant
therapy for prophylaxis or treatment of acute venous throm-
boembolism (VTE), and (2) to assess Joint Commission on
Accreditation of Health care Organizations (JCAHO) perfor-
mance measures for prevention and care of VTE. METHODS:
A retrospective chart review was performed by pharmacists at
32 community hospitals using an online standardized medication
use evaluation form. Compliance with ACCP recommendations
was assessed on the basis of dosage, duration and type of anti-
coagulant used. The following JCAHO performance measures
were calculated using standard deﬁnitions: #5-Objective conﬁr-
mation of clinically suspected VTE, #8-Anticoagulation overlap
of parenteral and warfarin therapy for patients with VTE, #9-
VTE patients with therapeutic International Normalized Ratio
(INR), #10-Platelet count monitoring for patients with VTE
receiving unfractionated heparin (UFH), #11-VTE patients on
warfarin with any INR ratio > 6 during hospitalization, #12-
VTE patients with a calculated creatinine clearance of <30
mL/min that received reduced medication dosage, #13-VTE
treatment for discharged patients with active cancer., #14-UFH
management by nomogram/protocol, and #16-VTE education
(inpatient). Results were expressed as proportions. RESULTS: A
total of 902 cases were assessed. The mean age of the patients
was 67.7 ± 16.9, 385 (42.7%) were males, and 104 (11.5%) had
active cancer. 732 (81.2%) patients received prophylaxis of VTE
while 170 (18.8%) received treatment for acute VTE. The
average length of therapy and hospital stay was 5.7 ± 5.3 and
7.8 ± 7.2 days respectively. Anticoagulant therapy was consis-
tent with ACCP recommendations in 78% of cases. Percent com-
pliance with JCAHO measure #5, #8, #9, #10, #11, #12, #13,
#14 and #16 were 82.9, 67.3, 28.0, 33.5, 0.0, 30.4, 14.7, 96.2,
and 44.3 respectively. CONCLUSION: Anticoagulant therapy
was in compliance with ACCP recommendations in majority of
cases (78%). Performance with some JCAHO measures was less
than optimal. Opportunities exist to improve the prevention and
treatment of VTE.
PQ2
COMPLIANCE AND PERSISTENCE WITH ASTHMA
MEDICATIONS: IMPLICATIONS OF ASTHMA SEVERITY
Cramer JA1, Suh DC2, Chao J3
1Yale University School of Medicine, West Haven, CT, USA, 2Rutgers
University, Piscataway, NJ, USA, 3sanoﬁ-aventis, Bridgewater, NJ, USA
OBJECTIVES: To evaluate differences in medication compliance
and persistence between patients with persistent (HP) and inter-
mittent or non-persistent (HNP) asthma according to the Health
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Plan Employer Data and Information Set (HEDIS) deﬁnitions, as
well as among the classes of asthma medications. METHODS:
A retrospective cohort analysis of the Integrated Health care
Information Services (IHCIS) administrative database evaluated
patients >/= 5 years of age with at least 2 prescriptions of asthma
medication. Asthma severity was classiﬁed as HP (n = 21,698)
or HNP (n = 11,967), in accordance with 2006 HEDIS criteria;
compliance, calculated as medication possession ratios (MPR)
and persistence, calculated as days supply before discontinua-
tion, switching, or augmentation, were measured in patients
treated with inhaled corticosteroids (ICS) (n = 3906 HP, n = 3856
HNP), leukotriene modiﬁers (LM) (n = 10,005 HP, n = 3823
HNP), and ICS + LABA combinations (n = 5893 HP, n =
3538 HNP) over a 1-year period. The study groups’ comparisons
were conducted using t-test or analysis of variance where appro-
priate. RESULTS: Overall, HP patients had higher MPRs with
all categories of medication (71 + 29%) compared with HNP
patients (43 + 27%, p < 0.001). Oral LM (78 + 27% HP, 51 +
29% HNP) were taken more frequently than ICS (55 + 30% HP,
31 + 21% HNP) or ICS + LABA combinations (65 + 28% HP,
p < 0.001, 43 + 25% HNP, p < 0.001). Persistence was longer
for LM (139 + 110 days HP, 90 + 86 days HNP), than for ICS
(64 + 72 days HP, 37 + 32 days HNP), or ICS + LABA (106 +
108 days HP, 66 + 73 days HNP, p < 0.001 for both). CON-
CLUSION: Both compliance and persistence remained subopti-
mal in this large asthmatic population, with HNP patients far
less consistent with their medication dosing and duration of use
than HP patients. LMs were used more consistently than inhaled
medications, with ICS being the least consistently used asthma
medication. Additional measures are needed to improve compli-
ance and persistence with these medications.
PQ3
A DECISION TREE APPROACH TO ESTIMATING COST
SAVINGS OF PAY FOR PERFORMANCE PROGRAMS IN A 
PPO SETTING
Legorreta AP1,Tian H2, Gilmore AS3, Ryskina K3, Legorreta G2,
Robinson M2,Taira D4, Chung R4
1UCLA School of Public Health, Woodland Hills, CA, USA, 2Health
Benchmarks, Woodland Hills, CA, USA, 3Health Benchmarks, Inc,
Woodland Hills, CA, USA, 4HMSA, Honolulu, HI, USA
OBJECTIVES: Pay-for-performance is gaining popularity and
acceptance as an approach to improve quality and efﬁciency of
health care in the U.S. However, little evidence regarding the eco-
nomic feasibility of this approach is currently available in the 
literature. Our objective was to examine the cost savings of 
a quality-based physician incentive program implemented in a
PPO setting. METHODS: Administrative claims data for
2003–2005 were obtained from a voluntary physician incentive
program implemented by a large non-proﬁt health plan in
Hawaii and used to calculate all costs and probabilities included
in the decision tree. Health plan members were categorized into
two groups: those who visited only physicians who participated
in the program and those who visited only non-participating
physicians during the study period. Rates of recommended care
for two evidence-based quality of care indicators—glycosylated
hemoglobin testing and lipid panel testing for members with dia-
betes—were compared between the two groups to determine
program effectiveness. Program costs included administrative
costs, the cost of quality of care evaluation, and physician reim-
bursement. Quality indicators that included several procedures
were assigned a weighted average cost. One year events included
severe diabetic complications. RESULTS: Average program cost
per enrollee was $21; the average cost of receiving the two tests
was $18; and the cost of developing relevant complications was
$6470. With the incentive program, the health plan saved
approximately $18 per adult diabetic considering just the two
indicators (i.e., total program costs were distributed across just
the two indicators for the purposes of this analysis), which trans-
lated to two year savings ranging from $2.5 to $6.7 million.
CONCLUSION: Physician reimbursement models built upon
evidence-based quality of care metrics may result in direct cost
savings to the health plan within a relatively short follow-up
time, in addition to positively affecting delivery of high quality,
recommended care.
PQ4
EVALUATION OF A MULTICENTER AND MULTIDISCIPLINARY
CONGESTIVE HEART FAILURE MANAGEMENT PROGRAM
Tan WS1, Heng BH2
1National Health care Group, Singapore, Singapore, Singapore,
Singapore, 2National Health care Group, Singapore, Singapore,
Singapore
OBJECTIVES: To investigate the impact of a multidisciplinary
disease management program implemented in 3 different hospi-
tals on the functional status, quality of life, and utilization of
hospital resources for patients with congestive heart failure
(CHF). The study also examined the ﬁnancial outcomes of the
program. METHODS: We evaluated the program by comparing
the rates of readmission (CHF) within 3- and 12-month of initial
discharge, the cumulative number of hospital days, the rate of
ED visits and ﬁnancial outcomes within 12 months of enrolment
for 431 patients given a multidisciplinary disease management
intervention against 141 patients who received usual care.
Changes in functional outcomes of patients on the program were
assessed at baseline and at six months using the 6-minute walk
distance and the New York Heart Association (NYHA) Func-
tional Classiﬁcation. The Minnesota Living with Heart Failure
Questionnaire was used to measure patients’ quality of life.
RESULTS: The intervention group had considerably and signif-
icantly lower hospital readmission rates than the control group
(5.6% vs. 15.6% within 3 months, P = 0.001, 13.2% vs. 29.8%
within 12 months, P < 0.001). The mean hospital days per
patient was also reduced from 3.3 ± 11.2 to 1.0 ± 3.5 (P < 0.001).
The number of emergency room visits (CHF) per patient was
46% lower for program patients. The mean 6-minute walk dis-
tance did not increase signiﬁcantly from baseline (P = 0.065)
whereas there was a 10% decline in NYHA score (P < 0.001)
and a markedly improvement quality of life were registered (P <
0.001). The return on investment was calculated to be 0.82.
CONCLUSION: The evaluation demonstrates that a multidisci-
plinary heart failure program led to improved functional status
and better quality of life while at the same time reduced utiliza-
tion of acute hospital resources.
